OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 2, 2011, Pages 315-324

  McBurnett, Keith ^a   Starr, H Lynn ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Adults; Attention deficit hyperactivity disorder; Methylphenidate; Stimulants

Indexed keywords

METHYLPHENIDATE;

ADULT; APPETITE; AREA UNDER THE CURVE; ARTICLE; ATTENTION DEFICIT DISORDER; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; INSOMNIA; NAUSEA; OPEN STUDY; OSMOTIC PRESSURE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; XEROSTOMIA;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG APPROVAL; DRUG DELIVERY SYSTEMS; HUMANS; METHYLPHENIDATE; TREATMENT OUTCOME;

EID: 78651428701     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.546058     Document Type: Article

References (76)

1. Wender PH. Attention deficit hyperactivity disorder in adults. Oxford University Press, Oxford; 1995
2. McBurnett K, Pfiffner LJ, Willcutt E, et al. Experimental cross-validation of DSM-IV types of Attention-Deficit/ Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 1999;38:17-24 (Pubitemid 29022483)
3. Lahey BB, Applegate B, McBurnett K, et al. DSM-IV field trials for attention deficit hyperactivity disorder in children and adolescents. Am J Psychiatry 1994;151:1673-85 (Pubitemid 24337603)
4. Hart EL, Lahey BB, Loeber R, et al. Developmental change in attention-deficit hyperactivity disorder in boys: a four-year longitudinal study. J Abnorm Child Psychol 1995;23:729-49
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. American Psychiatric Press, Inc., Washington, DC; 2000
6. Faraone SV, Upadhyaya HP. The effect of stimulant treatment for ADHD on later substance abuse and the potential for medication misuse, abuse, and diversion. J Clin Psychiatry 2007;68:e28
7. Applegate B, Lahey BB, Hart EL, et al. Validity of the age-of-onset criterion for ADHD: a report from the DSM-IV field trials. J Am Acad Child Adolesc Psychiatry 1997;36:1211-21 (Pubitemid 27381277)
8. Barkley RA, Biederman J. Toward a broader definition of the age-of-onset criterion for attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997;36:1204-10 (Pubitemid 27381276)
9. Rohde LA, Biederman J, Zimmermann H, et al. Exploring ADHD age-of-onset criterion in Brazilian adolescents. Eur Child Adolesc Psychiatry 2000;9:212-18
10. Faraone SV, Antshel KM. Diagnosing and treating attention-deficit/ hyperactivity disorder in adults. World Psychiatry 2008;7:131-6
11. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163:716-23 (Pubitemid 44464584)
12. Simon V, Czobor P, Balint S, et al. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 2009;194:204-11
13. Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007;164:942-8 (Pubitemid 46972911)
14. Polanczyk G, Rohde LA. Epidemiology of attention-deficit/hyperactivity disorder across the lifespan. Curr Opin Psychiatry 2007;20:386-92 (Pubitemid 46889666)
15. Centers for Disease Control and Prevention (CDC). Mental health in the United States. Prevalence of diagnosis and medication treatment for attentiondeficit/ hyperactivity disorder - United States, 2003. MMWR Morb Mortal Wkly Rep 2005;54:842-7
16. Barkley RA, Fischer M, Smallish L, Fletcher K. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry 2006;45:192-202 (Pubitemid 43151524)
17. Halmoy A, Fasmer OB, Gillberg C, Haavik J. Occupational outcome in adult ADHD: impact of symptom profile, comorbid psychiatric problems, and treatment: a cross-sectional study of 414 clinically diagnosed adult ADHD patients. J Atten Disord 2009;13:175-87
18. Sobanski E, Bruggemann D, Alm B, et al. Psychiatric comorbidity and functional impairment in a clinically referred sample of adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci 2007;257:371-7
19. Weiss M, Trokenberg-Hechtman L, Weiss G. ADHD in adulthood: a guide to current theory, diagnosis, and treatment. Johns Hopkins University Press, Baltimore, MD; 1999
20. Thompson AL, Molina BS, Pelham W Jr, Gnagy EM. Risky driving in adolescents and young adults with childhood ADHD. J Pediatr Psychol 2007;32:745-59
21. Molina BS, Pelham WE, Gnagy EM, et al. Attention-deficit/hyperactivity disorder risk for heavy drinking and alcohol use disorder is age specific. Alcohol Clin Exp Res 2007;31:643-54
22. Fischer M, Barkley RA, Smallish L, Fletcher K. Hyperactive children as young adults: driving abilities, safe driving behavior, and adverse driving outcomes. Accid Anal Prev 2007;39:94-105 (Pubitemid 44633822)
23. Wilens TE, Prince J, Biederman J. ADHD in adults. In: McBurnett K, Pfiffner LJ, editors. Attention deficit hyperactivity disorder: concepts, controversies, new directions.: Informa Healthcare, New York; 2008. p. 273-90
24. Biederman J, Monuteaux MC, Mick E, et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med 2006;36:167-79 (Pubitemid 43126141)
25. Biederman J, Petty CR, Monuteaux MC, et al. Adult psychiatric outcomes of girls with attention deficit hyperactivity disorder: 11-year follow-up in a longitudinal case-control study. Am J Psychiatry 2010;167:409-17
26. AACAP. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997;36:85-121S (Pubitemid 27435161)
27. American Academy of Pediatrics; Subcommittee on Attention-Deficit/ Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics 2001;108:1033-44
28. Blondis TA, Brown KA. The American academy of pediatrics ADHD practice guidelines: a critique. In: McBurnett K, Pfiffner LJ, editors, Attention deficit hyperactivity disorder: concepts, controversies, new directions. Informa Healthcare, New York; 2008. p. 331-9
29. Knouse LE, Safren SA. Current status of cognitive behavioral therapy for adult attention-deficit hyperactivity disorder. Psychiatr Clin North Am 2010;33:497-509
30. Solanto MV, Marks DJ, Wasserstein J, et al. Efficacy of meta-cognitive therapy for adult ADHD. Am J Psychiatry 2010;167:958-68
31. Young S, Amarasinghe JM. Practitioner review: non-pharmacological treatments for ADHD: a lifespan approach. J Child Psychol Psychiatry 2010;51:116-33
32. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 2010;71:754-63
33. Faraone SV, Spencer T, Aleardi M, et al. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2004;24:24-9 (Pubitemid 38134162)
34. Koesters M, Becker T, Kilian R, et al. Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol 2009;23:733-44
35. Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46:894-921 (Pubitemid 47067959)
36. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004;114:e1-8
37. Jasinski DR, Faries DE, Moore RJ, et al. Abuse liability assessment of atomoxetine in a drug-abusing population. Drug Alcohol Depend 2008;95:140-6
38. Michelson D, Read HA, Ruff DD, et al. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2007;46:242-51 (Pubitemid 46148423)
39. ter Laak MA, Temmink AH, Koeken A, et al. Recognition of impaired atomoxetine metabolism because of low CYP2D6 activity. Pediatr Neurol 2010;43:159-62
40. Pohl GM, Van Brunt DL, Ye W, et al. A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD). BMC Health Serv Res 2009;9:95[V1]
41. McNeil Pediatrics Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. Summary of Full Prescribing Information, 2010
42. Modi NB, Lindemulder B, Gupta SK. Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. J Clin Pharmacol 2000;40:379-88
43. Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 2003;60:204-11 (Pubitemid 36173129)
44. Coghill D, Seth S. Osmotic, controlled-release methylphenidate for the treatment of ADHD. Expert Opin Pharmacother 2006;7:2119-38
45. Wilens TE, Biederman J. The stimulants. Psychiatr Clin North Am 1992;15:191-222
46. Volkow ND, Wang GJ, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998;155:1325-31
47. Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 2000;21:RC121
48. Krause KH, Dresel SH, Krause J, et al. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett 2000;285:107-10 (Pubitemid 30227631)
49. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998;94:127-52
50. Kim BN, Lee JS, Cho SC, Lee DS. Methylphenidate increased regional cerebral blood flow in subjects with attention deficit/hyperactivity disorder. Yonsei Med J 2001;42:19-29 (Pubitemid 32274931)
51. Szobot CM, Ketzer C, Cunha RD, et al. The acute effect of methylphenidate on cerebral blood flow in boys with attention-deficit/hyperactivity disorder. Eur J Nucl Med Mol Imaging 2003;30:423-6 (Pubitemid 36692869)
52. Modi NB, Lindemulder B, Gupta SK. Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. J Clin Pharmacol 2000;40:379-88
53. Modi NB, Wang B, Noveck RJ, Gupta SK. Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system. J Clin Pharmacol 2000;40:1141-9
54. Modi NB, Wang B, Hu WT, Gupta SK. Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects. Biopharm Drug Dispos 2000;21:23-31
55. Auiler JF, Liu K, Lynch JM, Gelotte CK. Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR Food Evaluation (CAFE) Study. Curr Med. Res Opin 2002;18:311-16 (Pubitemid 35014548)
56. Adler LA, Zimmerman B, Starr HL, et al. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol 2009;29:239-47
57. Medori R, Ramos-Quiroga JA, Casas M, et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2008;63:981-9
58. Parasrampuria DA, Schoedel KA, Schuller R, et al. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans. J Clin Pharmacol 2007;47:1476-88 (Pubitemid 350115303)
59. Parasrampuria DA, Schoedel KA, Schuller R, et al. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users. J Clin Psychopharmacol 2007;27:459-67 (Pubitemid 47415043)
60. Spencer TJ, Biederman J, Ciccone PE, et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry 2006;163:387-95 (Pubitemid 44469379)
61. Cox DJ, Merkel RL, Penberthy JK, et al. Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: a pilot study. J Am Acad Child Adolesc Psychiatry 2004;43:269-75
62. Cox DJ, Humphrey JW, Merkel RL, et al. Controlled-release methylphenidate improves attention during on-road driving by adolescents with attention-deficit/hyperactivity disorder. J Am Board Fam Pract 2004;17:235-9
63. Cox DJ, Merkel RL, Moore M, et al. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder. Pediatrics 2006;118:e704-10 (Pubitemid 46089997)
64. Chronis-Tuscano A, Seymour KE, Stein MA, et al. Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting. J Clin Psychiatry 2008;69:1938-47
65. Reimherr FW, Williams ED, Strong RE, et al. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 2007;68:93-101
66. Ramos-Quiroga JA, Bosch R, Castells X, et al. Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate: a chart review of Spanish adults with attention-deficit hyperactivity disorder. CNS Drugs 2008;22:603-11 (Pubitemid 351836038)
67. Spencer TJ, Mick E, Surman CB, et al. A randomized, single-blind, substitution study of OROS methylphenidate (concerta) in ADHD adults receiving immediate release methylphenidate. J Atten Disord 21 May 2010. [Epub ahead of print]
68. Adler LD, Nierenberg AA. Review of medication adherence in children and adults with ADHD. Postgrad Med 2010;122:184-91
69. Biederman J, Monuteaux MC, Spencer T, et al. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry 2008;165:597-603 (Pubitemid 351705336)
70. Wilens TE, Adamson J, Monuteaux MC, et al. Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents. Arch Pediatr Adolesc Med 2008;162:916-21
71. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003;111:179-85 (Pubitemid 36071051)
72. Konstenius M, Jayaram-Lindstrom N, Beck O, Franck J. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study. Drug Alcohol Depend 2010;108:130-3
73. Diller L. ADHD in the college student: is anyone else worried? J Atten Disord 2010;14:3-6
74. Safren SA, Sprich SE, Cooper-Vince C, et al. Life impairments in adults with medication-treated ADHD. J Atten Disord 2010;13:524-31
75. Spencer TJ, Adler LA, Meihua Q, et al. Validation of the adult ADHD investigator symptom rating scale (AISRS). J Atten Disord 2010;14:57-68
76. Barkley RA, Murphy KR, Fischer M. ADHD in adults: what the science says. 1st edition. Guilford Press, New York; 2007